Mumbai: Alkem is doubling down on its manufacturing ambitions, significantly scaling up its Ujjain project as it sharpens focus on future capacity and growth in formulations.
Investment Push Accelerates
The company’s board has approved raising the investment cap to INR 1036 crores for its upcoming greenfield formulations manufacturing facility in Ujjain. This marks a sharp jump from the earlier approved INR 533 crores. The phased investment signals a stronger commitment to expanding domestic manufacturing capabilities at a time when demand visibility remains steady.
Land And Project Scope
The expansion follows the allotment of about 30 acres of land in Phase 2 of the DMIC Vikram Udyogpuri industrial area, confirmed on March 18, 2026. The site is earmarked for a formulations manufacturing unit, positioning it as a key addition to Alkem’s production network in central India.
Strategic Capacity Build
The increased outlay suggests Alkem is recalibrating its scale expectations for the facility. By nearly doubling the investment, the company appears to be planning higher capacity or more advanced infrastructure than initially envisaged. The move reflects management’s confidence in long-term pharmaceutical demand and the need for expanded production capabilities.
Long Term Growth Focus
This investment aligns with Alkem’s broader strategy to strengthen its manufacturing footprint and support future product pipelines. With phased deployment, the company retains flexibility while ensuring the project can scale alongside market opportunities and regulatory requirements.
The disclosure was made under SEBI’s listing regulations and formally communicated to stock exchanges on April 2, 2026, as detailed in the company filing.
Disclaimer: This article is based on company filings and is for informational purposes only. It does not constitute investment advice. Readers should verify details independently before making any financial decisions.
